Nosocomial Infections – A Growing Problem
Contain Clostridium Difficile before it strikes.
Flexi-Seal™ FMS is a closed system designed to minimize the spread of infection by containing infectious liquid/semi-liquid stool.
It has been scientifically proven in-vitro to contain the spread of C. difficile.1 The closed system may help to reduce environmental contamination from other potentially pathogenic bacteria such as extended-spectrum beta-lactamase (ESBL) producing bacteria and methicillin-resistant Staphylococus aureus (MRSA).
Help reduce complications and cut costs
Nosocomial infections are a common complication of hospitalization and are associated with higher rates of morbidity and mortality.2 These infections lead to extended hospital stays and an increase in treatment and diagnostics that result in increased costs.3,4
- Infection-related costs can exceed $13,675 per case.5
- Increases length of stay by 3.6 days per patient.6
- Up to 20% of hospitalized patients can become infected with C. difficile with a considerable impact on length of stay.6
Customer Relations Center
For more information, please contact the Customer Relations Center at 1-800-465-6302.
1 Jones S, Towers V, Welsby S, Wishin J, Bowler P. Clostridium difficile Containment Properties of a Fecal Management System: An In Vitro Investigation. Ostomy Wound Management, 2011;57(10):38–49.
2 Geffers C, Gastmeier P. Nosocomial infections and multidrug-resistant organisms – epidemiologicaldata from KISS. DtschArzteblInt 2011; 108(6): 87-93.
3 Beyersmann J, Gastmeier P, Grundmann H, Bärwolff S, Geffers C, Behnke M, Rüden H, Schumacher M. Use of multistate models to assess prolongation of intensive care unit stay due to nosocomial infection. Infect Control Hosp Epidemiol. 2006;27(5):493-499.
4 Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271(20):1598-601.
5 O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007:28(11):1219-1227.
6 Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. CID, 2002;34:346-53.